Hippo signaling in acute kidney injury to chronic kidney disease transition : Current understandings and future targets
Copyright © 2023 Elsevier Ltd. All rights reserved..
Acute kidney injury (AKI)-to-chronic kidney disease (CKD) transition is a slow but persistent progression toward end-stage kidney disease. Earlier reports have shown that Hippo components, such as Yes-associated protein (YAP) and its homolog Transcriptional coactivator with PDZ-binding motif (TAZ), regulate inflammation and fibrogenesis during the AKI-to-CKD transition. Notably, the roles and mechanisms of Hippo components vary during AKI, AKI-to-CKD transition, and CKD. Hence, it is important to understand these roles in detail. This review addresses the potential of Hippo regulators or components as future therapeutic targets for halting the AKI-to-CKD transition.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Drug discovery today - 28(2023), 8 vom: 01. Aug., Seite 103649 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Habshi, Tahib [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
AKI-to-CKD transition |
|---|
| Anmerkungen: |
Date Completed 24.07.2023 Date Revised 25.07.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.drudis.2023.103649 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357702190 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357702190 | ||
| 003 | DE-627 | ||
| 005 | 20231226073148.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.drudis.2023.103649 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1192.xml |
| 035 | |a (DE-627)NLM357702190 | ||
| 035 | |a (NLM)37268185 | ||
| 035 | |a (PII)S1359-6446(23)00165-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Habshi, Tahib |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hippo signaling in acute kidney injury to chronic kidney disease transition |b Current understandings and future targets |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.07.2023 | ||
| 500 | |a Date Revised 25.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Acute kidney injury (AKI)-to-chronic kidney disease (CKD) transition is a slow but persistent progression toward end-stage kidney disease. Earlier reports have shown that Hippo components, such as Yes-associated protein (YAP) and its homolog Transcriptional coactivator with PDZ-binding motif (TAZ), regulate inflammation and fibrogenesis during the AKI-to-CKD transition. Notably, the roles and mechanisms of Hippo components vary during AKI, AKI-to-CKD transition, and CKD. Hence, it is important to understand these roles in detail. This review addresses the potential of Hippo regulators or components as future therapeutic targets for halting the AKI-to-CKD transition | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a AKI-to-CKD transition | |
| 650 | 4 | |a YAP/TAZ | |
| 650 | 4 | |a acute kidney injury | |
| 650 | 4 | |a chronic kidney disease | |
| 650 | 4 | |a hippo signaling | |
| 650 | 7 | |a Transcription Factors |2 NLM | |
| 700 | 1 | |a Shelke, Vishwadeep |e verfasserin |4 aut | |
| 700 | 1 | |a Kale, Ajinath |e verfasserin |4 aut | |
| 700 | 1 | |a Lech, Maciej |e verfasserin |4 aut | |
| 700 | 1 | |a Gaikwad, Anil Bhanudas |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug discovery today |d 1998 |g 28(2023), 8 vom: 01. Aug., Seite 103649 |w (DE-627)NLM095449159 |x 1878-5832 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2023 |g number:8 |g day:01 |g month:08 |g pages:103649 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.drudis.2023.103649 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2023 |e 8 |b 01 |c 08 |h 103649 | ||